MGMT and glioblastoma: O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation is present in approximately 35% of newly diagnosed GBM [14] and has been shown to be a predictive biomarker of response to DNA alkylating chemotherapeutics, such as temozolomide, since methylation can compromise the ability to repair DNA damage [15,16].